December 13, 2021
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100
F Street, NE
Washington, D.C. 20549
| Attn: | Jane Park |
| Laura Crotty |
| Re: | Immix Biopharma, Inc. (the “Company”) | |
| Registration Statement on Form S-1/A | ||
| File No. 333-259591 | ||
| Acceleration Request |
| Requested Date: December 15, 2021 | ||
| Requested Time: 4:45 p.m., Eastern Standard Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1/A (File No. 333-259591) (the “Registration Statement”) to become effective on Wednesday, December 15, 2021, at 4:45 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
Securities and Exchange Commission, p. 2
December 13, 2021
| Very truly yours, |
| ThinkEquity LLC |
| By: | /s/ Eric Lord | |
| Name: | Eric Lord | |
| Title: | Head of Investment Banking |
| cc: | Ilya Rachman, Immix Biopharma, Inc. |
| Jeffrey Fessler, Sheppard, Mullin, Richter & Hampton LLP | |
| Anthony Epps, Dorsey & Whitney LLP |